PRESS RELEASE

FOR IMMEDIATE RELEASE

CEL-SCI Corporation issues restricted shares to Ergomed for partial settlement of receivable

London, UK - 21 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that it has entered into an agreement with its co-development partner, CEL-SCI Corporation (NYSE: CVM) ('CEL-SCI'), whereby CEL-SCI will issue 480,000 shares of restricted stock which, upon registration, may be sold subject to a volume restriction of no more than five per cent of the trading volume in any single day.

ENDS

Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Dan Weng (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit:http://ergomedplc.com

Ergomed plc published this content on 21 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 August 2017 06:17:05 UTC.

Original documenthttp://otp.investis.com/clients/uk/ergomed/rns/regulatory-story.aspx?cid=1407&newsid=910220

Public permalinkhttp://www.publicnow.com/view/6EB948CC34DE2EE8884654EDCC45D20371EB5DFA